Clinical Trials Directory

Trials / Completed

CompletedNCT02040844

Phase III Cat-PAD Follow-on Study

An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
430 (actual)
Sponsor
Circassia Limited · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment. The study is an optional follow-up study to a phase III double-blind, placebo controlled, Cat-PAD study; no further investigational product is administered.

Conditions

Interventions

TypeNameDescription
DRUGReceived Cat-PAD Treatment 1 in Study CP007 [NCT01620762]
DRUGReceived Cat-PAD Treatment 2 in Study CP007 [NCT01620762]
DRUGReceived Cat-PAD Treatment 3 in Study CP007 [NCT01620762]

Timeline

Start date
2014-02-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2014-01-20
Last updated
2018-06-15
Results posted
2018-05-14

Source: ClinicalTrials.gov record NCT02040844. Inclusion in this directory is not an endorsement.